ERIC 2022 | Using genomics to better understand the pathogenesis of CLL & for early disease diagnosis
Richard Rosenquist
• 7 Oct 2022
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, comments on how the use of high-throughput sequencing technologies has allowed researchers to learn more about the pathogenesis of chronic lymphocytic leukemia (CLL). Dr Rosenquist explains how genomic analysis can provide information about what phase of the disease the tumor cell is in and how it can help identify driver mutations. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
